Zastaprazan
Small moleculeexperimental
Clinical trial activity
14 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
4
Phase 4
2
Earliest trial started Dec 21, 2017 (NCT03383042)
Timeline
Indications
Mechanism of action
- Cytochrome P450 2C19INHIBITOR
CYP2C19 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07115173 | Phase 4 | Dec 1, 2025 | Sungkyunkwan University |
| NCT07265466 | Phase 1 | Nov 17, 2025 | Onconic Therapeutics Inc. |
| NCT07268820 | Phase 4 | Jul 7, 2025 | Incheon St.Mary's Hospital |
| NCT07181538 | Phase 1 | Feb 4, 2025 | Onconic Therapeutics Inc. |
| NCT06850480 | Phase 3 | Dec 5, 2024 | Livzon Pharmaceutical Group Inc. |
| NCT06439563 | Phase 3 | Oct 22, 2024 | Onconic Therapeutics Inc. |
| NCT05712681 | Phase 1 | Feb 28, 2023 | Onconic Therapeutics Inc. |
| NCT05814809 | Phase 1 | Sep 30, 2022 | Onconic Therapeutics Inc. |
| NCT05448001 | Phase 3 | Aug 15, 2022 | Onconic Therapeutics Inc. |
| NCT05443984 | Phase 3 | Jan 17, 2022 | Onconic Therapeutics Inc. |
| NCT05181124 | Phase 1 | Mar 5, 2021 | Onconic Therapeutics Inc. |
| NCT05194046 | Phase 1 | Nov 18, 2020 | Onconic Therapeutics Inc. |
| NCT04282954 | Phase 2 | Nov 15, 2019 | Jeil Pharmaceutical Co., Ltd. |
| NCT03383042 | Phase 1 | Dec 21, 2017 | Jeil Pharmaceutical Co., Ltd. |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Onconic Therapeutics Inc. | For profit | 9 | 9 | 2 | 2020 |
| Jeil Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 2 | 2017 |
| Incheon St.Mary's Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Livzon Pharmaceutical Group Inc. | For profit | 1 | 1 | 1 | 2024 |
| Sungkyunkwan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1